** Shares of drug developer Adial Pharmaceuticals ADIL.O rise as much as 68.8% to $1.30
** ADIL says U.S. FDA agreed with co's plan to use a specific approach called "in vitro bridging strategy" to support the development of AD04, to treat alcohol-use disorder in heavy-drinking patients
** This approach involves using existing data and lab tests to show that the new version of AD04 is equivalent to the previous version
** Co is developing the drug for its upcoming late-stage trial, set to begin this year
** Last year, AD04 showed safety and tolerability consistent with an existing treatment
** ADIL fell 42.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.